Matritech completes $1 million financing:
This article was originally published in Clinica
Cancer diagnostic company Matritech has sold 331,532 shares to raise an aggregate of $1 million. The Newton, Massachusetts company will use the proceeds to fund operating costs and capital expenditure. The company's nuclear matrix protein (NMP) technology correlates levels of NMP in body fluids to the presence of cancer.